High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program

High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program

Bibliographic Details
Main Authors:	Armstrong, M, Falahati, A, Braun, O, Schmidt, W, Gough, S, Newsome, P
Format:	Conference item
Published:	2010

Similar Items

High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program
by: Armstrong, M, et al.
Published: (2010)

EFFECTS OF TWO YEARS OF LIRAGLUTIDE TREATMENT ON FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: ANALYSIS OF THE LEAD-2 EXTENSION TRIAL
by: Armstrong, M, et al.
Published: (2010)

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
by: Armstrong, M, et al.
Published: (2013)

Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme
by: Armstrong, M, et al.
Published: (2013)

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program
by: Armstrong, M, et al.
Published: (2013)

Gut-liver axis in nonalcoholic fatty liver disease (NAFLD)
by: Koo, Yolanda Wei Ling
Published: (2023)

Managing NAFLD in Type 2 Diabetes: the effect of lifestyle interventions
by: Parry, S, et al.
Published: (2020)

In-vitro validation of potential modulators of non-alcoholic fatty liver disease (NAFLD)
by: Tang, Daryl Woon Tat
Published: (2024)

Does the presence of NAFLD influence prescribing behaviour in Type 2 diabetes?
by: Whyte, MB, et al.
Published: (2017)

MRE in NAFLD: promising but further validation is required
by: Ryan, J, et al.
Published: (2018)

Insights into the role of PPARβ/δ in NAFLD
by: Tan, Nguan Soon, et al.
Published: (2018)

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis
by: Vali, V, et al.
Published: (2020)

kadar leptin pada populasi non diabetes dengan dan tanpa non alcoholic fatty liver disease (NAFLD)
by: , SOFIA, Noor Asyiqah, et al.
Published: (2010)

Oxidative stress in NAFLD : role of nutrients and food contaminants
by: Rives, Clémence, et al.
Published: (2021)

The effect of modified alternate day calorie restriction on non-alcoholic fatty liver disease (NAFLD)
by: Yusoff, Khairiah Mat
Published: (2018)

A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
by: Moolla, A, et al.
Published: (2019)

Impact of Pparβ/δ deletion in non-parenchymal cells - liver physiology and disease (NAFLD)
by: Chen, Kelvin Jiapeng
Published: (2018)

The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD)
by: Savic, D, et al.
Published: (2020)

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
by: Mózes, FE, et al.
Published: (2021)

The effect of modified alternate day calorie restriction (MACR) on non-alcoholic fatty liver disease (NAFLD)
by: Johari, Muhammad Izzad
Published: (2017)

Distinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity
by: Subudhi, Sonu, et al.
Published: (2022)

Hepatic iron is the major determinant of serum ferritin in NAFLD patients.
by: Ryan, J, et al.
Published: (2017)

Towards the first antibody-free serum biomarker assay for NAFLD
by: Gangadharan, B, et al.
Published: (2017)

Towards the first antibody-free serum biomarker assay for NAFLD
by: Gangadharan, B, et al.
Published: (2017)

Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and Type 2 diabetes? Results from the WELCOME study
by: Scorletti, E, et al.
Published: (2014)

Reply to: non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
by: Pavlides, M, et al.
Published: (2021)

The (travel) times they are a changing : a computational framework for the diagnosis of non-alcoholic fatty liver disease (NAFLD)
by: Benjamin, Alex (Alex Robert)
Published: (2017)

CD4+ T cells mediate the development of liver fibrosis in high fat diet-induced NAFLD in humanized mice
by: Her, Zhisheng, et al.
Published: (2020)

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis
by: Selvaraj, EA, et al.
Published: (2021)

Splanchnic balance of free fatty acids, endocannabinoids and lipids in subjects with NAFLD
by: Kotronen, A, et al.
Published: (2010)

Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity
by: Régnier, Marion, et al.
Published: (2020)

Multi-parametric MRI can diagnose steatohepatitis and cirrhosis in patients with NAFLD
by: Pavlides, M, et al.
Published: (2014)

Coffee consumption and NAFLD: a community based study on 1223 subjects
by: Graeter, Tilmann, et al.
Published: (2015)

Genome wide in-vivo functional genetic screen to identify novel modulators of Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Lian, Ying
Published: (2022)

Lessons on drug development: a literature review of challenges faced in nonalcoholic fatty liver disease (NAFLD) clinical trials
by: Chen, Joel Yeh Siang, et al.
Published: (2023)

NASH-associated gut microbiome in human microbiota-associated NAFLD mouse model
by: Tan, Jovi Siying
Published: (2023)

Utility of human relevant preclinical animal models in navigating NAFLD to MAFLD paradigm
by: Chua, Damien, et al.
Published: (2023)

Utility of human relevant preclinical animal models in navigating NAFLD to MAFLD paradigm
by: Chua, D, et al.
Published: (2022)

The potential of the FSP1cre-Pparb/d-/- mouse model for studying juvenile NAFLD
by: Chen, Jiapeng, et al.
Published: (2020)

Patient transcriptomic based in vivo functional genetic dissection of NAFLD for therapeutic target identification
by: Moo, Jia Rong
Published: (2023)